Last reviewed · How we verify
Gemcitabine, nucleoside analogue; intravenous
At a glance
| Generic name | Gemcitabine, nucleoside analogue; intravenous |
|---|---|
| Sponsor | Array BioPharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Cemiplimab in Adults With Cervical Cancer (PHASE3)
- Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients (PHASE2)
- A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: